



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2011

---

## **"Nanomania" ante portas of neurooncology?**

Weller, M ; Wick, W

DOI: <https://doi.org/10.1007/s11060-010-0508-y>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-50524>

Journal Article

Published Version

Originally published at:

Weller, M; Wick, W (2011). "Nanomania" ante portas of neurooncology? *Journal of Neuro-Oncology*, 104(2):613-614.

DOI: <https://doi.org/10.1007/s11060-010-0508-y>

## “Nanomania” *ante portas* of neurooncology?

Michael Weller · Wolfgang Wick

Received: 16 October 2010 / Accepted: 13 December 2010 / Published online: 25 December 2010  
© Springer Science+Business Media, LLC. 2010

### To the Editor

There is currently no standard of care for recurrent glioblastoma. Accordingly, there is an urgent medical need for new therapeutic approaches in this setting. Novel treatment approaches are often received with great hopes by patients and relatives. Nevertheless, it is mandatory that all novel treatment approaches, not only pharmacological treatments, are subjected to standardized evaluations of safety and efficacy.

In this regard, German neuro-oncologists have been exposed to pressure from patients and relatives to introduce the new therapy referred to as *intratumoral thermotherapy*, developed by MagForce Nanotechnologies, for many years. Finally and fortunately, data of a “phase II trial” were recently published in the *Journal of Neuro-Oncology* [1]. In contrast to the title of this article, we would like to point out that neither safety nor efficacy were demonstrated:

- (i) Safety was an issue. 15 patients experienced epileptic seizures in the context of the treatment. Even the authors raise the possibility that patients might benefit from prophylactic anticonvulsants if they opt for this treatment modality. From the quality of life perspective, it is important to note that all metallic materials

including dental fillings, crowns and implants within 40 cm of the treatment area had to be removed, for safety reasons.

- (ii) Efficacy could not be demonstrated simply as a consequence of the study design. The experimental treatment was combined with fractionated stereotactic radiotherapy at 30 Gy in 2 Gy fractions. The combination of an experimental treatment modality with an established treatment modality like stereotactic radiotherapy in an uncontrolled phase II trial is inappropriate to demonstrate efficacy.
- (iii) 24 of 59 patients had some treatment (resection 11, radiotherapy 2, chemotherapy 17) for the same recurrence subsequently treated with intratumoral thermotherapy. No effort was made to dissect the role of the various treatment measures administered at recurrence.
- (iv) The authors indicate that “data on any subsequent treatments for tumor progression following the thermo/radiotherapy were not systematically collected”. Accordingly, the impact of the experimental treatment on the overall survival estimate is impossible to evaluate. Progression-free survival was not assessed and cannot easily be addressed since this treatment precludes further MRI monitoring for life because of artefact. Yet, overall survival at 2 years from recurrence was the primary end point and additional treatment measures at further recurrence are likely to have influenced the treatment results.
- (v) The authors state that analysis was by intention to treat, but it remains unclear what happened to the seven patients that were included, but did not fulfil inclusion criteria. Curiously, analysis of efficacy is based on 59 patients whereas analysis of safety is on 66 patients.

---

M. Weller (✉)  
Department of Neurology, University Hospital Zurich,  
Frauenklinikstrasse 26, 8091 Zurich, Switzerland  
e-mail: michael.weller@usz.ch

W. Wick  
Department of Neuro-Oncology, Heidelberg University  
Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg,  
Germany  
e-mail: wolfgang.wick@med.uni-heidelberg.de

Some minor comments need to be made, too:

- (vi) The authors claim that randomization for recurrent glioblastoma is “extremely difficult” and that a randomized assessment of intratumoral thermotherapy was not possible. This statement is proven wrong by the series of randomized trials in that setting that have been performed in the recent years, both using local treatments such as immunotoxins or chemotherapy, e.g. for cilengitide [2], erlotinib [3], enzastaurin [4] or cediranib [5].
- (vii) The authors cite Stummer et al. [6] as a reference for the value of surgery for recurrent glioblastoma which is not the content of this work.
- (viii) The hypothesis that PET and SPECT are as good as MRI to monitor disease progression has never been addressed in a clinical study.

Altogether, this trial has a study design that a priori did not allow to draw conclusions regarding efficacy. Yet, substantial efforts are made in claiming efficacy in the Discussion section, based on historical comparisons which are inappropriate. This unjustified claim of efficacy is worrisome because two of the authors are employees of MagForce Nanotechnologies. This is mentioned as a disclosure, but the conflict of interest section says “none”.

Michael Weller, Zurich, Switzerland

Wolfgang Wick, Heidelberg, Germany

intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. *J Neuro-Oncol*. doi: [10.1007/s11060-010-0389-0](https://doi.org/10.1007/s11060-010-0389-0)

2. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittmer SM, Nippgen J, Picard M, Nabors LB (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide in recurrent glioblastoma multiforme. *J Clin Oncol* 26:5610–5617
3. Van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MCM, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJB, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. *J Clin Oncol* 27:1268–1274
4. Wick W, Puduvalli VK, Chamberlain M, Van den Bent M, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Enzastaurin versus lomustine in the treatment of recurrent intracranial glioblastoma: a phase III study. *J Clin Oncol* 28:1168–1174
5. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Xu J, Liu Q, van den Bent M (2010) A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. ESMO 2010, Milan, Italy, LBA 7
6. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol* 7:392–401

## References

1. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A (2010) Efficacy and safety of